[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-risk-factors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-risk-factors":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627328","phase-2-vascular-intervention-strategies-trial-for-alzheimers-100627328",false,"NCT07447206","Vascular Intervention Strategies Trial for Alzheimer's","Vascular Intervention Strategies Trial for Alzheimer's (VISTA)","VISTA","Inclusion Criteria:\n\n* APOE ε4 carrier (homozygote or heterozygote)\n* LDL-C of 100-250 mg\u002FdL\n* Systolic blood Pressure (SBP) 130-180 mm Hg\n* Age 50-75 years\n* Fluency in English\n* No dementia based on medical record review\n* Male or post-menopausal female\n\nExclusion Criteria:\n\n* One minute standing SBP \\\u003C 110 mm Hg\n* Arm circumference prevents from accurate BP measurement with use of available devices\n* Lost weight of \\> 10% unintendedly (within the past 6 months),\n* Contraindications to blood pressure and cholesterol lowering medications\n* Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)\n* Evidence of dementia based on medical record review\n* Living in a skilled nursing or rehabilitation facility\n* Receiving palliative or hospice care\n* Bipolar illness or schizophrenia\n* Drug or alcohol disorder\n* Receiving chronic opioid therapy\n* Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)\n* Severe loss of visual, hearing or communication ability\n* Organ transplant\n* History of stroke, symptomatic HF or left ventricular ejection fraction \\\u003C 35%\n* ESRD or eGFR \\\u003C 20 ml\u002Fmin \u002F1.73m2\n* Does not consent to be contacted or to have their medical record reviewed for research purposes\n* Concurrent participation in another clinical trial","ALL","50 Years","75 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.",[28,29,30],"Hypertension","Hypercholesterolemia","Dementia Risk Factors",[32,33,28,29,34,35,36],"APOE ε4 carriers","Dementia risk","Vascular risk factors","Pharmacist-led intervention","Feasibility study","NOT_YET_RECRUITING","2026-04-27",{"date":40,"type":41},"2026-05-04","ACTUAL",{"date":43,"type":22},"2026-05",{"date":45,"type":22},"2028-06",{"name":47,"class":48},"University of Southern California","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100586952","the-reminder4care-program-for-older-adults-supported-by-residential-and-daycare-facilities-100586952","NCT06922071","The REMINDER4Care Program for Older Adults Supported by Residential and Daycare Facilities","REMINDER4Care","Inclusion Criteria:\n\n* Aged 65 years and older\n* RDF users\n* Elementary reading and writing skills\n\nExclusion Criteria:\n\n* Have a clinical diagnosis of dementia and\u002For Mini-Mental State Examination (MMSE) scores below the cutoff for the presence of dementia (MMSE \\\u003C 22-27, depending on education level)\n* Have a psychiatric or neurological condition that impairs cognition in the long term\n* Have sensory and functional deficits that compromise their participation in the neuropsychological assessment and throughout the intervention sessions",true,"65 Years",{"count":60,"type":22},100,[62],"NA","Dementia incidence is rising, posing a public health challenge, but 45% of cases can be prevented by addressing modifiable risk factors. Multidomain trials show that lifestyle changes can improve cognitive function and reduce dementia risk (like the FINGER trial). The REMINDER program, a Portuguese-based dementia risk reduction protocol, was developed for community-dwelling older adults aged 55 and above. However, older adults in Residential and Daycare Facilities (RDF) have distinct needs that demand program adaptation to ensure its relevance and effectiveness. In addition, more studies are needed to evaluate the impact of multidomain interventions with older adults in RDF.\n\nTo address these challenges, the REMINDER4Care program was developed as a tailored, multidomain intervention to reduce dementia risk. It emphasizes social and cognitive engagement and advances its adaptation and evaluation in Residential and Daycare Facilities (RDF). To assess efficacy, the investigators will perform a Randomized Controlled Trial.",[30,65,66],"Prevention","Cognitive Health",[30,65,68,69,70,71],"Health","Aging","Residential and Daycare Facilities","Lifestyle","RECRUITING",{"date":74,"type":41},"2026-05-01",{"date":76,"type":41},"2025-05-01",{"date":78,"type":22},"2026-12-31",{"name":80,"class":48},"University of Coimbra"]